24家中外生物技术和制药翘楚亮相J.P会议周|2020China Focus@San Fracisco路演专场

一年一度的J.PMorgan Healthcare Conference一直是享誉生物医药产业的全球战略风向标和项目对接交易的盛会。旧金山时间2020年1月12日，第38届J.P Morgan Healthcare Conference 会议期间，2020 China Focus会议上，由誉衡生物独家赞助，Ginger Ding 女士（MyBioGate 投资分析全球总监）主持的路演专场中，数十家创新药物，医疗器械，医疗服务健康，生物医药产业全自动化，AI人工智能辅助新药研发等领域公司带来了精彩的演讲展示。

China Focus 路演专场从第一次推出，就受到了跨境平台合作上最为著名积极的龙头企业鼎力支持。恒瑞医药、FC Capital、勃林格殷格翰、复星、江苏省产业技术研究院、步长医药的等企业大佬场场出席，可见China Focus 路演的影响力和效力满满。随着国内生物医药企业国际间合作越来越多，各类创新主体都有着独特的自身战略。个体优势，只有结合市场，集思广益，才能做出效益最大化的合作及选择，国际化合作将是未来全球药企发展的必然趋势。

China Focus 路演专场还专门请到了六位重量级嘉宾分享其成功海内外项目对接，融资等成功的经验。嘉宾们针对中美商业文化差异进行了深入交流讨论，大家一致认为：与中国企业打交道的方式越来越国际化、专业化、便利化，对中外商业互通接受度也越来越高，China Focus路演专场正在为更多的国内药企、国际药企、以及海内外投资机构提供更有深度的对接服务，并承担着真正意义上的“引路人”角色。

在随后的China Focus路演专场，依次进行项目展示（公司推广）的是誉衡生物、拜耳（中国）、挚盟医药、开拓药业（Kintor）、惠瑞生物、瑞顺生物、索元生物医药、剂泰医药、Maintect GmbH、Celsion、Targovax（OSE：TRVX）、Flow Pharma、Curevo Vaccine、Cerenetex、Dyadic International、Virometix、OncoGenesis、Strateos、Gero、VivaLNK、Canary Speech、TECLens、Erythra、Avotres等24家中外肿瘤、慢性乙型肝炎、中风、传染病疫苗、医疗物联网平台等业界生物技术和制药的翘楚公司。项目方对企业进行了全方位展示，并和慕名而来的投资人进行现场答疑与深度对接。

Company Presentation Reference:

Targovax

Goal: Activate immune system to inhibitcancer

Target: Lung cancer, melanoma

Method: Develop checkpoint inhibitor toactivate immune system➜produce more T cells

Platform:

◆ Oncolytic virus➜Totreat T cell targeting specific tumor

◆ Neoantigen vaccine

Flowpharma

Goal: To treat virtual disease, cancer

Target: Breast cancer/ Ebola/ cervicalcancer

Platform:

◆FlowVAX, a neoantigen cancer vaccine;high yield but low cost

◆SEAPAC Delivery platform (cancervaccines need a good delivery technology)

Strategy:

Virus in the targeted cells (APC) canrecognize neopeptide➜produce cytokines➜release and kill cancer cells.

FlowVAX Workflow (4 weeks total)

◆Sequence cancer cell

◆AI screen novel neoantigens

◆In vitro confirmation

Key advantages:

◆Each APC only recognize one neoantigen

◆Intensive T cell activation

◆Safer, cheaper

◆No immune response

Cerenetex

Focuses: delay in stroke care; delayedtreatment

Solutions: cerebral hemodynamics thatproduced by blood flow

Headphone could pick up acoustic signalproduced by cerebral hemodynamics➜record➜cloud

Application: Reflect whether the stroketreatment is effective

Dyadic

Platform: C1 Fungal gene expressionplatform

C1: myoliophthna thermophila fromalkaline soil in Russia

Advantages:High purity of target protein screted, low cost

Application:glycoengineering---C1 isbetter than yeast, faster, higher yield

Maintest

Target: wet age related-maculardegeneration (WAMD)

Problem: ¼ patients shows no effect withcurrent treatment

Strategy: anti-angiogenesis treatment viainhibition of VEGF

Stage: They have already developed theantibody AB125, and tested in vitro/ in vivo; confirmed in initial clinicaltrial.

Workplan:

◆ 1.5-2 years: develop kit

◆ 3-5 years: clinical trail

ZhimengBiopharma

Target: 1. Anti-virus/ HBV; 2. CNS: epilepsy, pain, stroke

Pipeline:

HBV—Caspid inhibitor; RNA destabilizer;TLR8 agonist

Epilepsy --- KCNQ 2/3 opener

Pain --- KCNQ 2/3 opener

Stroke --- PSD95 antagonist

Virometix

Platform:

◆ SVLP: synthetic virus-like particle(30nm)

◆ synthetic antigen mimetic (SAM)

DenovoBiopharma

Goal: Using AI driven method to treatschizophrenia, AD

Strategy: transform failed drugs intosuccessful personalized medicine

From the drugs that fail in phase 3➜search new markers➜ modify the drug➜phase 3

Oncogenesis

Goal: To treat cervical cancer

Current situation: HPV DNA screen (noteffective)

Strategy:

new proteinbiomarker –CerMark

iPapself-assembly collector➜CerMark POC analyzer

Advantages:

Patientsdon’t need to return to clinic for Pap test

Highspecific; high sensitivity

Curevo Vaccine

Targeted diseases: shingles; chickenpox

Strategy: CRV101, a synthetic TLR4 agonist,already in phase 1, suitable for children and adults, not a live virus. Lookfor parterner, look for $20 million for funding

Suzhou KintorPharma

Target: cancer

Strategy: monotherapy

IPO preparation

HuiruiBiopharma Company

Target: infectious disease, autoimmunedisease, tumor, leukemia

Gap: current anti-flu medicine induces drugresistance

Products: BH103

Decreaselung cytokine levels

Notexpect to induce drug resistance

Celsion

Platform: noval nanoparticle-basedtechnology

◆ LTSL (lipidsome for delivery)---ThermoDOX

◆ Theroplas—GEN-1 immunotherapy

UsingDNA plasmid coded for therapeutic protein as a drug

Milestone events:

Targeting hepatocellular carcinoma

ThermaDOX+ radiofrequency ablation (RFA)➜expand the treatment zone➜survivaltime increase 2 years

WYZE Biotech

Target: acute myeloid leukemia (AML)

Platform: DNT cells (CD3+ CD4- CD8- cells)=double negative T cells ( DNT)

DNTcells are a novel therapy to target AML, effective in eliminating AML

Strateos

Goal: accelerating discovery

Platform: using AI, open access,fully-automated, programmable lab

Strategy:Automated chemical synthesis➜auto biotesting➜productautomated➜chemical synthesis

GloriaBioscience

Products: GLS-010 fully anti-human PL-1(naturally screened from transgenic rat platform)

Preliminary Results: Shows impressiveantitumor activity when treated on cervical cancer

Avotres

Pipeline: 3 year development plan, exit by2022

Strategy: Find a way to treat regulatory Tcells (which can secrete cytokines)

Product: AVT002

Gero

Goal: drug discovery against complexdiseases

Solution:“Deep phenotype”—model of diseaseprogression with actionable biomarker from large unbiased human cohorts.

Machine learning

Ongoing: Using immune senescence, metabolichealth, senescent cells burden as targets to develop anti-aging drugs.

Bayer

Right timing and Right places to developthe company in China.

Focus on:cardiovascular andcerebrovascular diseases; diabetes; respiratory disease; cancer; infectiousdisease

Viva LNK

Product: one small device can continuouslymeasure blood pressure, respiration, ECG/HR, temperature, heart failuredetection.

Canary Speech

Speech can reflect the central nervoussystem.

Strategy: identify more than 2000biomarkers in language, to detect neurodegenerative diseases such asAlzheimer’s disease and Parkinson’s’ disease.